# Study to Evaluate the Efficacy and Safety of MEDI9929 (AMG 157) in Adult Subjects With Inadequately Controlled, Severe Asthma

> **NCT02054130** · PHASE2 · COMPLETED · sponsor: **MedImmune LLC** · enrollment: 584 (actual)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** Placebo
- **DRUG:** MEDI9929 70 mg
- **DRUG:** MEDI9929 210 mg
- **DRUG:** MEDI9929 280 mg

## Key facts

- **NCT ID:** NCT02054130
- **Lead sponsor:** MedImmune LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-12-13
- **Primary completion:** 2016-12-12
- **Final completion:** 2017-03-01
- **Target enrollment:** 584 (ACTUAL)
- **Last updated:** 2018-12-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02054130

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02054130, "Study to Evaluate the Efficacy and Safety of MEDI9929 (AMG 157) in Adult Subjects With Inadequately Controlled, Severe Asthma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02054130. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*